Xtandi

Chemical Nameenzalutamide
Dosage FormCapsule (oral; 40 mg); Tablet (oral; 40 mg, 80 mg)
Drug ClassInhibitors
SystemMale reproductive
CompanyAstellas Pharma
Approval Year2012

Indication

  • For the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer
Last updated on 4/26/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xtandi (enzalutamide) Prescribing Information.2012Astellas Pharma US Inc., Northbrook, IL
Document TitleYearSource
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. 2022The Lancet
Association of novel androgen receptor axis-targeted therapies with diarrhea in patients with prostate cancer: a Bayesian network analysis. 2022Frontiers in Medicine
Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. 2022Journal of the National Cancer Institute
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. 2022Anti-Cancer Drugs
Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: a systematic review. 2022Urologic Oncology: Seminars and Original Investigations
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. 2021Prostate Cancer and Prostatic Diseases
Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis. 2021Minerva Urology and Nephrology
Novel androgen receptor inhibitors in non-metastatic, castration-resistant prostate cancer: a systematic review and network meta-analysis. 2021Frontiers in Oncology
Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: a systematic review. 2021Journal of Geriatric Oncology
Efficacy and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.2021Frontiers in Oncology
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. 2021Prostate Cancer and Prostatic Diseases
Apalutamide, enzalutamide, and darolutamide for non‑metastatic castration‑resistant prostate cancer: a systematic review and network meta‑analysis.2020International Journal of Clinical Oncology
Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. 2020European Urology
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. 2020Prostate Cancer and Prostatic Diseases
A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.2020Clinical Genitourinary Cancer
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. 2020Journal of Oncology Pharmacy Practice
Systemic management for non-metastatic castration-resistant prostate cancer. 2020American Journal of Clinical Oncology
Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. 2020Prostate Cancer and Prostatic Diseases
Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis.2020Journal of Pharmacy and Pharmaceutical Sciences
Comparative efficacy of combined radiotherapy, systemic therapy, and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a network meta-analysis and systematic review.2020Frontiers in Oncology
Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer.2019Medicine
Third-line treatment and 177Lu-PSMA radio ligand therapy of metastatic castration-resistant prostate cancer: a systematic review.2018European Journal of Nuclear Medicine and Molecular Imaging
Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer.2018Value in Health
Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration‑resistant prostate cancer: a systematic review.2017Asian Journal of Andrology
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. 2017Current Medical Research and Opinion
First‐line non‐cytotoxic therapy in chemotherapy‐naive patients with metastatic castration‐resistant prostate cancer: a systematic review of 10 randomised clinical trials. 2017BJU International
Document TitleYearSource
EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. 2022European Association of Urology
Prostate cancer, version 2.2019.2019Journal of the National Comprehensive Cancer Network